Slc1A1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute |
Value |
| Protein Name |
Sodium/Glutamate Transporter 1 |
| Gene Symbol |
SLC1A1 |
| UniProt ID |
P43005 |
| NCBI Gene ID |
6507 |
| Protein Family |
SLC1 family (EAAT) |
| Molecular Weight |
~57 kDa |
| Subcellular Location |
Plasma membrane |
| Expression |
Brain, kidney, intestine |
-}}
SLC1A1 (Sodium/Glutamate Transporter 1), also known as EAAT3 (Excitatory Amino Acid Transporter 3), is a high-affinity glutamate transporter responsible for clearing excitatory neurotransmitters from the synaptic cleft. This protein plays crucial roles in preventing excitotoxicity and maintaining glutamate homeostasis in the brain.
- Sodium coupling - 3 Na+ ions per glutamate
- Proton coupling - 1 H+ cotransport
- Counter-transport - 1 K+ counter-transport
- Electrogenic - Net positive charge transport
- Glutamate - Primary substrate
- Aspartate - Alternative substrate
- Cystine - In exchange for glutamate (system Xc-)
- Glutamate clearance - Impaired in epileptic tissue
- Excitotoxicity - Contributes to seizure progression
- Therapeutic targeting - Modulators under investigation
- Excitotoxicity - Glutamate-induced neuronal damage
- Synaptic function - Altered glutamate recycling
- Therapeutic implications - Glutamate modulators
- Dopaminergic neurons - Vulnerable to excitotoxicity
- Metabolic stress - Impaired glutamate transport
- Neuroprotection - EAAT3 enhancement
- Genetic association - SLC1A1 variants linked to OCD
- Cortico-striatal circuits - Glutamate dysregulation
- Therapeutic implications - Glutamate-targeting drugs
- Glutamate transport enhancers - Increase EAAT3 activity
- Allosteric modulators - Target transporter conformation
- Gene therapy - AAV-mediated expression
- Biomarkers - SLC1A1 as disease marker
- Neuroimaging - PET ligands for EAATs
- Combination therapy - With antioxidants
SLC1A3 (EAAT1) represents a promising therapeutic target for multiple neurological conditions. The transporter's role in glutamate homeostasis makes it an attractive target for modulating excitotoxicity.
| Approach | Mechanism | Disease | Status |
|----------|-----------|---------||
| EAAT1 agonists | Increase uptake | Epilepsy | Preclinical |
| EAAT1 modulators | Allosteric modulation | Migraine | Research |
| Gene therapy | Increase expression | AD | Experimental |
Transport across the BBB remains a challenge for EAAT1-targeted drugs. Novel delivery approaches include:
- Receptor-mediated transcytosis
- Nanoparticle delivery systems
- Intranasal administration
EAAT1 expression patterns may serve as biomarkers for:
- Glial activation in neuroinflammation
- Disease progression in MS
- Treatment response in epilepsy
Several SNPs in SLC1A3 have been associated with:
- Migraine susceptibility
- Epilepsy risk
- ALS progression
The study of Slc1A1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kanai Y, Hediger MA. Primary structure and functional characterization of a high-affinity glutamate transporter. Nature. 1992;360(6403):467-471. PMID:7502583
- Proper EA, Oestreicher AB, Jansen GH, et al. Immunohistochemical characterization of excitatory amino acid transporters in the human hippocampus. Neuroscience. 2000;99(3):493-505. PMID:10559285
- Arnold PD, Sicard T, Burroughs E, et al. Glutamate system genes associated with OCD. Arch Gen Psychiatry. 2008;65(6):690-700. PMID:18515852